Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCRATCH: SBRT + Systemic Therapy vs Systemic Therapy Alone in BCLC Stage C HCC
NCT07274774Phase 2Suspended
- Sponsor
- Shandong Cancer Hospital
- Start
- Nov 2025
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hepatocellular carcinoma (HCC) (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: Overall Survival at 48 months. Started Nov 2025; status: suspended.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07274774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07274774.